A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
Status:
Recruiting
Trial end date:
2030-01-01
Target enrollment:
Participant gender:
Summary
This is a Phase 3, open-label, randomized trial designed to evaluate the RFS of TURBT
followed by cretostimogene grenadenorepvec versus TURBT followed by observation for the
treatment of participants with IR-NMIBC.